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Frequency of Low-Density
Lipoprotein Receptor Gene Mutations
in Patients With a Clinical Diagnosis of Familial
Combined Hyperlipidemia in a Clinical Setting
Fernando Civeira, MD, PHD,* Estibaliz Jarauta, MD,* Ana Cenarro, PHD,*
Angel L. Garcı´a-Otı´n, PHD,* Diego Tejedor, PHD,† Daniel Zambo´n, MD, PHD,‡
Miguel Mallen, BSC,§ Emilio Ros, MD, PHD,‡ Miguel Pocovı´, PHD§
Zaragoza and Derio, Spain
Objectives The purpose of this study was to determine the frequency of mutations in the low-density lipoprotein receptor
(LDLR) and apolipoprotein B (APOB) genes in consecutive patients with a clinical diagnosis of familial combined
hyperlipidemia (FCH) in a nonresearch setting.
Background The lipid phenotype frequently overlaps in familial hypercholesterolemia (FH) and FCH. Detection of causative
mutations in LDLR or APOB provides an unequivocal diagnosis of FH, but such genetic testing has not been sys-
tematically performed in FCH.
Methods We used Lipochip (Progenika, Derio, Spain), a microarray that includes 203 causative mutations in LDLR and
4 APOB defects, to investigate 143 unrelated FCH patients.
Results Mutations of LDLR were found in 28 patients (overall prevalence, 19.6%). No APOB defects were found. Com-
pared with patients who had a normal LDLR gene, patients with mutations had lower waist circumference (p 
0.02); significantly (p  0.005) higher total cholesterol, non–high-density lipoprotein cholesterol, low-density li-
poprotein cholesterol, and apoB; nonsignificantly (p  0.063) lower triglycerides; and a lower frequency of diabe-
tes mellitus (22% vs. 0%, respectively; p  0.002). Total cholesterol and apoB levels showed the best receiver-
operator characteristics curves in the prediction of LDLR mutations, with areas under the curve (95% CI: of
0.750 (95% confidence interval [CI]: 0.647 to 0.853) and 0.744 (95% CI: 0.636 to 0.851), respectively. Total
cholesterol of 335 mg/dl and apoB of 185 mg/dl were the best thresholds for diagnosis of LDLR mutations.
Conclusions Screening for LDLR defects is advisable for patients with a clinical diagnosis of FCH showing high total choles-
terol or apoB levels. Diagnostic criteria for FH should not exclude patients whose personal and familial lipid val-
ues appear to fit the clinical criteria of FCH. (J Am Coll Cardiol 2008;52:1546–53) © 2008 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.06.050l
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ihe low-density lipoprotein receptor (LDLR) is a cellular
urface protein that recognizes and internalizes low-density
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ccepted June 2, 2008.ipoprotein (LDL) particles. Dysfunction of the LDLR
auses familial hypercholesterolemia (FH), one of the most
ommon inherited metabolic diseases in humans (1). Ho-
ozygous FH is a very rare condition, but the frequency of
eterozygous FH is close to 1 in 500 persons in most
See page 1554
opulations. Elevated blood concentrations of LDL-
holesterol, a high risk of early-onset coronary heart disease,
nd extravascular lipid deposits such as arcus cornealis and
endon xanthomas characterize FH (1). Blood triglycerides
n FH usually are in the normal range; thus, the typical lipid
bnormality is an isolated elevation of LDL-cholesterol.
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November 4, 2008:1546–53 LDLR Mutations in FCHowever, patients with FH disclose higher triglyceride
evels than do their unaffected relatives and/or age-matched
ubjects from the general population (2,3); and as many of
5% of heterozygous FH patients present a mixed hyper-
ipidemia phenotype, with elevation of both LDL-
holesterol and triglycerides (4). This subgroup of hypertri-
lyceridemic FH represents a diagnostic challenge, because
ixed hyperlipidemia with familial presentation is charac-
eristic of familial combined hyperlipidemia (FCH), an-
ther common inherited lipid abnormality characterized by
remature coronary heart disease (5). In fact, the usual
iagnostic criteria for FH contemplate that either serum
riglycerides should be normal (200 mg/dl) (6) or the
iagnosis must be considered with caution in patients with
ypertriglyceridemia (7). The problem is compounded by
he equivocal diagnostic criteria for FCH. This disorder is
ssociated with variable lipid phenotypes, both in affected
ersons and family members, with a clinical expression that
s closely related to visceral fat accumulation, and the
ecently proposed FCH criterion of an elevated apolipopro-
ein (apo) B level (8) is also present in FH. Moreover,
endon xanthomas, a key diagnostic feature, are clinically
etectable in only 40% of FH patients after the fourth
ecade of life (9,10).
The overlapping clinical presentation of FCH and FH
ith high triglycerides has been previously suspected in the
imon Broome Registry in the United Kingdom (11),
herein patients with a clinical diagnosis of FH but no
endon xanthomas disclosed lower blood cholesterol and
igher triglycerides, blood pressure, and body mass index
han did patients with tendon xanthomas. These differences
uggested to the authors that the diagnostic criteria used in
hat cohort misclassified as FH cases some patients with
CH (11). Evidence of such misclassification was reported
n a 3-generation pedigree with an apparent diagnosis of
CH in whom a defective LDLR allele was shown to cause
he familial hypercholesteromic phenotype (12).
A definitive diagnosis of FH can be made by molecular
esting showing a pathogenic defect in the LDLR or APOB
enes. Such an approach should unequivocally clarify the
iagnosis between FH and FCH in doubtful cases. To our
nowledge, the LDLR and APOB genes have not been
ystematically screened in subjects with a clinical diagnosis
f FCH. The aim of this study was to describe the frequency
f LDLR and APOBmutations in a large group of unrelated
ubjects who had received a diagnosis of FCH, based on the
resence of mixed hyperlipidemia in the index case, a
ariable lipid phenotype in first-degree relatives, and ab-
ence of tendon xanthomas.
ethods
tudy subjects. From October 2005 to June 2007, consec-
tive patients ages 25 years with a clinical diagnosis of
CH attending 2 lipid clinics in Spain were recruited into a
rotocol approved by the local review boards and provided Bnformed consent. The diagnosis
f FCH was based on the pres-
nce of primary combined hyper-
ipidemia, with off-treatment se-
um cholesterol and triglyceride
evels above the gender- and age-
djusted 90th percentile for the
panish population (13), serum
otal apoB levels 120 mg/dl,
nd at least 1 first-degree relative
ith hyperlipidemia (total cho-
esterol and/or triglycerides
90th percentile). Off-treatment
ipid values of first-degree family
embers were obtained from
linical records, and they were
lassified into the following categories: 1) normolipidemic
90th percentile for total cholesterol and triglycerides); 2)
ype 2a (90th percentile total cholesterol and 90th
ercentile triglycerides); 3) type 2b (90th percentile total
holesterol and 90th percentile triglycerides); and 4) type
(90th percentile total cholesterol and 90 percentile
riglycerides). Gender- and age-adjusted 90th percentile
utpoints for the Spanish population were used (13). For the
urpose of this study, additional inclusion criteria were
erum LDL-cholesterol 190 mg/dl or non–high-density
ipoprotein (HDL)-cholesterol 220 mg/dl when serum
riglycerides were 400 mg/dl. Exclusion criteria were
econdary causes of hyperlipidemia, presence of tendon
anthomas in the proband or in any family member, a
revious clinical or molecular diagnosis of FH in a first-
egree relative, or very high triglycerides level (1,000
g/dl). To exclude the presence of xanthomas uncovered by
hysical examination, Achilles tendons were examined by
onography with a standard protocol shared by the 2 clinics,
s described (14).
linical and laboratory determinations. All subjects were
ssessed for family history of early-onset coronary heart
isease, clinical history, medication use, demographic char-
cteristics, adiposity measures, cardiovascular risk factors,
nd presence of tendon xanthomas. Diabetes mellitus was
efined as fasting glucose level 126 mg/dl or treatment
ith antidiabetic agents.
In asymptomatic subjects, fasting blood for baseline
iochemical profiles was drawn after at least 4 weeks
ithout hypolipidemic drug treatment. In patients with
rior coronary heart disease, baseline lipid values were
btained from clinical records. Cholesterol and triglycerides
ere determined by standard enzymatic methods. HDL-
holesterol was measured by a precipitation technique.
DL-cholesterol was estimated with the Friedewald equa-
ion when serum triglycerides were 400 mg/dl. Non–
DL-cholesterol was calculated as total cholesterol minus
DL-cholesterol. Both apoB and lipoprotein(a) were de-
ermined by using immunoturbidimetry (Unimate 3, Roche,
Abbreviations
and Acronyms
Apo  apolipoprotein
CI  confidence interval
FCH  familial combined
hyperlipidemia
FH  familial
hypercholesterolemia
LDL  low-density
lipoprotein
LDLR  low-density
lipoprotein receptor gene
ROC  receiver-operator
characteristicasel, Switzerland).
G
A
(
d
m
b
t
p
q
p
r
d
s
9
t
b
n
i
(
L
u
p
p
a
(
t
S
S
f
f
o
v
t
u
u
a
a
c
s
t
t
f
a
T
c
m
d
f
a
r
t
s
i
p
v
m
c
a
a
a
D
t
i
s
s
R
C
s
i
d
d
p
e
3
F
t
t
t
m
L
h
n
l
i
L
i
t
w
D
w
A
L
h
m
L
L
s
A
T
c
L
m
i
w
T
1
(
1548 Civeira et al. JACC Vol. 52, No. 19, 2008
LDLR Mutations in FCH November 4, 2008:1546–53enetic studies. The screening of mutations in LDLR and
POB genes was performed with Lipochip, version 4
Progenika, Derio, Spain). This platform is a microarray
evice that includes the diagnosis of 203 different causative
utations in the LDLR gene and 4 mutations in the
inding domain of apoB. The microarray design, fabrica-
ion, and quality controls, the target deoxyribonucleic acid
reparation and hybridization, the microarray scanning and
uantification, and the genotyping software have been
reviously described in detail (15). Lipochip version 4
ecognizes 88% of the 230 different LDLR mutations
etected in Spain thus far. The overall specificity and
ensitivity obtained for all mutations tested was 99.7% and
9.9%, respectively (16). Because the most common muta-
ions are included in the array, after testing5,000 deoxyri-
onucleic acid samples from patients with a clinical diag-
osis of FH, we can be confident that Lipochip version 4
dentifies 95% of genetic defects causing FH in Spain
D. Tejedor, personal communication, December 2007).
arge rearrangements in the LDLR gene were analyzed
sing a method based on quantitative fluorescent multiplex
olymerase chain reaction (17).
The APOE genotype, defined by the common polymor-
hisms p.Cys130Arg (C112R) and p.Arg176Cys (R158C),
nd the 2 rare variants p.Arg154Ser (R136S) and p.Lys167del
L149del), was determined by specific pyrosequencing reac-
ions on a PSQ96MA instrument (Biotage AB, Uppsala,
weden).
tatistical analyses. Data are presented as means ( SD)
or continuous variables (medians and interquartile ranges
or variables with a skewed distribution) and as frequencies
r percentages for categorical variables. Differences in mean
alues were assessed using t tests or the Mann-Whitney U
est, as appropriate. Categorical variables were compared
sing chi-square tests. Univariate logistic regression was
sed to determine the ability of clinical variables and lipid
nd apo concentrations to discriminate between cases with
nd without LDLR defects, and crude odds ratios with 95%
onfidence intervals (CIs) were calculated. Because of a
kewed distribution, triglyceride levels were transformed to
heir natural logarithm for analyses. We determined the
hreshold values of these variables for best diagnostic per-
ormance of the presence of a LDLR defect based on
nalysis of receiver-operator characteristic (ROC) curves.
he ROC curves were constructed by using mutation
arriers as the disease group and the subjects without
utations as the nondisease group. Because all cases of
iabetes mellitus occurred in subjects without genetic de-
ects, the odds ratios calculated in the logistic regression
nalysis gave inconsistent results and very large CIs. For this
eason, the odds ratio for diabetes was calculated by using
he 2-tailed Fisher exact test.
Multivariate logistic regression analysis with the forward
election based on likelihood ratio was used to examine the
ndependent association of different variables with the
resence of FH-causing genetic defects. The independent rariables used in this model were as follows: gender, age, body
ass index, waist circumference, the serum levels of total
holesterol, LDL-cholesterol (or non–HDL-cholesterol),
poB, and natural logarithm triglycerides, and presence or
bsence of a total cholesterol level above the gender- and
ge-specific 95th percentile for the Spanish population (13).
iabetic subjects and subjects disclosing the APOE 2/2 geno-
ype or rare APOE variants were excluded from the multivar-
ate analysis. All statistical analyses were performed with SPSS
oftware (version 13.0, SPSS, Inc., Chicago, Illinois), with
ignificance set at p  0.05.
esults
linical characteristics. A total of 143 unrelated FCH
ubjects, 93 men and 50 women ages 51  11 years, were
ncluded in the study. A personal history of coronary heart
isease and a family history of early-onset coronary heart
isease were present in 30 (21%) patients and 44 (31%)
atients, respectively. Mean plasma total cholesterol, triglyc-
rides, and HDL-cholesterol levels were 326  57 mg/dl,
52  175 mg/dl, and 42  14 mg/dl, respectively.
requency of LDLR mutations. A functional LDLR mu-
ation was found in 28 (19.6%) patients. No APOB muta-
ions were detected. The clinical and biochemical charac-
eristics of patients with (LDLR) and without (LDLR)
utations are shown in Table 1. In comparison with
DLR patients, patients shown to be LDLR disclosed
igher serum levels of total cholesterol, LDL-cholesterol,
on–HDL-cholesterol, and apoB. In contrast, triglyceride
evels were higher, although not reaching statistical signif-
cance, in LDLR patients compared with those in
DLR patients (p  0.059). The frequency of mutations
n women (28%) was nonsignificantly (p  0.063) higher
han in men (15%). The LDLR patients also had a higher
aist circumference, even after adjustment for gender.
iabetes was present in 26 LDLR patients (22.6%) and
as absent in LDLR patients.
POE genotype. The APOE genotype of 2 patients in the
DLR group was E2/E2, indicating that their combined
yperlipidemia phenotype was due to dysbetalipoproteine-
ia. In addition, 1 E3/E3 woman and 1 E3/E3 man in the
DLR group were heterozygous for the rare alleles
149del and S136, respectively. Both mutations have been
hown to be associated with dyslipidemia (18,19). No rare
POE variants were present in the LDLR group.
ypes of LDLR mutations. The clinical and biochemical
haracteristics, APOE genotype, and LDLR defect of the 28
DLR patients is shown in Table 2. A total of 22 different
utations distributed along the whole gene were found,
ndicating high molecular heterogeneity. Three subjects
ere heterozygous for the double defect 1061-8TC/
726I; the mutations 91GT, 518delG, 829GA, and
133AC were found in 2 subjects each. The 2 mutations
1255TC and 1359-3CT) have not been previously
eported, although they have been found in the Spanish FH
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November 4, 2008:1546–53 LDLR Mutations in FCHopulation. The proportion between negative-receptor and
efective-receptor mutations was 1:3 (5 subjects had nega-
ive alleles, 16 subjects had defective alleles, and 7 patients
ad splicing mutations with undetermined effect on LDL
eceptor activity) (Online Table).
redictors of LDLR mutations by logistic regression and
OC analyses. Crude odds ratios associated with the
resence of a LDLR mutation are shown in Table 3. The
ariables that contributed positively were absence of diabe-
es, total cholesterol 95th percentile, and serum concen-
rations of total cholesterol, LDL-cholesterol, non–HDL-
holesterol, and apoB. Waist circumference was negatively
ssociated with presence of a LDLRmutation. The best area
nder the curve in the ROC analysis was given by apoB,
lthough without significant differences from the values
btained for total cholesterol and LDL-cholesterol.
To assess whether any combination of variables could
mprove the prediction of having a LDLR defect, indepen-
ent associations were sought by multivariate logistic regres-
ion. The concentration of apoB was the sole independent
actor associated with a LDLR mutation, with odds ratio
.028 (95% CI: 1.013 to 1.044; p  0.001). The area under
he curve of apoB in the ROC analysis was 0.744 (95% CI:
.636 to 0.851; p  0.001). When apoB was excluded from
haracteristics of Patients With a Clinical Diagnosisf FCH According to Presence of LDLR Mutations
Table 1 Characteristics of Patients With a Clinical Diagnosisof FCH According to Presence of LDLR Mutations
LDLR
(n  115)
LDLR
(n  28) p Value
Age, yrs 51.5 10.8 49.4 12.9 0.388
Gender, men/women 79/36 14/14 0.063
Smokers, n (%) 0.443
Never 48 (41.7) 14 (50.0)
Current 28 (24.3) 8 (28.6)
Former 39 (33.9) 6 (21.4)
Prior coronary heart disease,
n (%)
26 (22.6) 4 (14.3) 0.332
Diabetes mellitus, n (%) 26 (22.6) 0 (0) 0.002
Hypertension, n (%) 45 (39.1) 9 (32.1) 0.494
Body mass index, kg/m2 28.2 3.75 27.2 3.44 0.168
Waist circumference, cm 97.3 10.2 92.1 9.6 0.020
Achilles tendon thickness, mm* 4.84 0.64 4.81 0.65 0.804
Lipids and lipoproteins, mg/dl
Total cholesterol 318 56 357 54 0.001
LDL-cholesterol (78/23)† 226 56 268 56 0.002
Non–HDL-cholesterol 277 53 310 4 0.003
HDL-cholesterol 41 12 47 18 0.129
Triglycerides 301 (226–464) 248 (217–361) 0.059
ApoAI 127 23 126 32 0.863
ApoB 167 30 199 41 0.001
Lipoprotein(a) 23.0 (7.20–70.0) 20.4 (4.87–68.6) 0.737
ata are means SD or medians (interquartile ranges). *Maximum thickness of bilateral tendons
easured at sonography. †Numbers of measurements available for LDLR and LDLR patients,
espectively, are shown in parentheses where values were missing because the Friedewald
quation was inadequate to estimate LDL-cholesterol (i.e., serum triglycerides 400 mg/dl).
issing values for LDL-cholesterol did not differ between groups, p  0.136.
Apo apolipoprotein; FCH familial combined hyperlipidemia; HDL high-density lipoprotein;
DL low-density lipoprotein; LDLR low-density lipoprotein receptor; LDLR absence of LDLR
utation; LDLR  presence of LDLR mutation.he model, total cholesterol was the independent associa- nion, with odds ratio 1.019 (95% CI: 1.009 to 1.030; p 
.001), and the area under the curve in the ROC analysis
as 0.750 (95% CI: 0.647 to 0.853; p  0.001). The ROC
tatistics were also used to evaluate sensitivity and specificity
f thresholds for these variables. The optimal threshold was
hosen so that the sum of the sensitivity and the specificity
o discriminate LDLR from LDLR subjects was maxi-
al. A total cholesterol level 335 mg/dl and apoB 185
g/dl provided the best cutoff values, with sensitivities and
pecificities of 61% and 72% and 61% and 74%, respectively.
Considering the association of LDLR mutations with
linical characteristics and serum cholesterol and apoB
alues, we calculated their frequency in various subgroups.
s shown in Figure 1, the prevalence of LDLR mutations
ncreased from 19.6% in the overall series to 41.7% among
ondiabetic subjects with normal APOE genotype and a
otal cholesterol level 335 mg/dl or apoB 185 mg/dl.
iscussion
his study shows that a substantial number of patients with
clinical diagnosis of FCH disclose a functional mutation in
he LDLR gene and thus should be classified as FH bearers.
hese results are novel and firmly support the previously
uspected notion that patients with clinical FH who present
ith hypertriglyceridemia and a lipid phenotype overlap-
ing that of FCH may be misdiagnosed as having FCH
11). They also suggest that FCH is a phenotype rather than
disease, and that FH could be considered as one of its
auses.
Hypertriglyceridemia is a not uncommon feature of FH that
ay have several causes. First, LDL particles carry small
mounts of triglycerides; therefore, if there is a large number of
irculating LDL particles, some degree of triglyceride elevation
ight be expected. Second, in addition to clearing LDL from
he circulation, the LDLR removes some triglyceride-carrying
ery low-density and intermediate-density lipoproteins (l), and
t has been clearly demonstrated that severe LDLR protein
efects, especially those affecting repeat 5 of the binding
omain, can interfere with intermediate-density lipoprotein
ptake by liver cells (20). Third, the coexistence in the same
atient of FH with other genetic lipid abnormalities, such as
CH or dysbetalipoproteinemia (21), could explain the con-
omitant and severe increases of cholesterol and triglycerides
bserved in some patients with a molecular diagnosis of FH.
astly and probably more important, many common genetic
nd environmental factors contribute to triglyceride elevations
n the population (22), and their influence could be magnified
n the presence of LDLR defects. For example, the hypertri-
lyceridemic effect of a frequent functional mutation in the
ipoprotein lipase gene (D9N) is higher in FH patients than in
he general population (23). Our results support the existence
f common polygenic and environmental triglyceride-raising
actors for several reasons: the LDLRmutations found are also
resent in normotriglyceridemic FH; all types of mutations,
ot only severe ones, occurred in our FCH patients; and the
Clinical and Biochemical Characteristics, APOE Genotype, LDLR Mutation, and LipoproteinPhenotype of First-Degree F mily Members of the 28 Subjects With Mixed Hyperlipidemia and Presence of LDLR Mutation
Table 2 Clinical and Biochemical Characteristics, APOE Genotype, LDLR Mutation, and LipoproteinPhenotype of First-Degree Family Members of the 28 Subjects With Mixed Hyperlipidemia and Presence of LDLR Mutation
Gender
Age,
yrs
BMI,
kg/m2
CVD
(Age of
Onset, yrs)
Total
Cholesterol,
mg/dl
Triglycerides,
mg/dl
Non–HDL-
Cholesterol,
mg/dl
HDL-
Cholesterol,
mg/dl
ApoB,
mg/dl
APOE
Genotype LDLR Mutation*
Lipoprotein Phenotype of
First-Degree Family Members,
Normal/IIa/IIb/IV
Male 61 26.8 Yes (59) 401 221 368 33 217 E3/E3 135CG 3/1/0/0
Male 39 30.7 No 423 379 385 38 256 E3/E3 E31X 1/1/1/0
Male 38 22.4 No 437 219 401 36 304 E3/E4 E31X 3/1/0/0
Male 30 29.9 No 273 506 248 25 143 E3/E3 E31X1061-8TC  T726I 1/0/1/1
Male 34 25.7 No 317 483 286 31 163 E3/E3 3131_3132insT 4/2/2/0
Female 39 20.9 No 336 159 290 46 191 E3/E3 3131GA 4/1/1/0
Female 47 23.1 No 398 167 349 49 189 E3/E3 C95G  1587-1GC 0/0/1/0
Male 43 33.4 No 368 275 333 35 188 E3/E4 Asp168Asn 1/1/2/0
Female 27 28.1 No 359 362 307 52 234 E3/E3 C173SfsX33 1/1/1/0
Female 73 31.0 No 438 218 384 54 272 E3/E3 C173SfsX33 3/1/2/0
Male 54 26.0 No 307 810 270 37 170 E3/E3 E277K 4/2/0/0
Female 67 26.1 No 345 360 304 41 224 E3/E3 E277K 1/0/1/1
Female 62 26.9 No 304 250 254 50 178 E3/E3 941-39 C/T 2/0/1/0
Male 56 31.4 Yes (54) 360 330 319 41 160 E3/E3 1061-8TC  T726I 4/1/1/0
Female 65 31.2 No 377 210 331 46 201 E3/E3 1061-8TC  T726I 2/0/1/0
Female 72 27.8 No 294 217 225 69 139 E3/E3 1061-8TC  T726I 6/1/1/0
Female 59 31.0 No 311 309 255 56 249 E3/E4 Q378P 2/1/2/0
Female 37 24.5 No 326 147 229 97 145 E3/E3 Q378P 3/1/1/0
Female 45 19.6 No 398 169 311 87 225 E2/E3 T454N 3/1/1/0
Male 44 27.4 No 453 217 405 48 179 E3/E3 A540T 1/3/1/0
Male 46 26.6 Yes (45) 444 258 409 35 176 E3/E3 N564H  c.2393_2401del9 3/1/1/0
Male 48 22.5 Yes (47) 275 247 250 25 154 E3/E3 1706-10 GA 3/2/0/0
Female 63 28.3 No 365 251 326 39 202 E3/E3 P655L 1/1/1/0
Female 52 29.1 No 323 450 283 40 158 E3/E3 G701S 2/2/0/0
Male 40 24.5 No 310 203 277 33 213 E3/E3 c.2390-1G/C 1/0/4/0
Female 59 29.6 No 386 247 304 82 217 E3/E3 c.1359-3CT 3/2/1/0
Male 32 29.1 No 292 219 265 27 201 E3/E4 Y419H 1/0/1/0
Male 51 29.1 No 387 636 323 64 212 E3/E3 170556CT 2/0/1/0
A further description of the LDLR mutations can be found at http://www.ucl.ac.uk/ldlr.
APO  apolipoprotein; BMI  body mass index; CVD  cardiovascular disease; HDL  high-density lipoprotein; LDLR  low-density lipoprotein receptor.
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November 4, 2008:1546–53 LDLR Mutations in FCHbserved 1 to 3 proportion of negative- to defective-receptor
lleles was similar to that reported for the overall Spanish FH
opulation (24).
DLR mutations are rare in subjects with mixed hyper-
ipidemia and diabetes. One important observation of our
tudy is the striking difference in the frequency of type 2
iabetes mellitus between the groups with and without LDLR
utations. Clearly, FCH is closely linked with obesity, insulin
esistance, and diabetes (25); and the presence of these meta-
actors Associated With Presence of LDLR Mutations in Patients W
Table 3 Factors Associated With Presence of LDLR Mutations
Variables in Univariate Logistic Regression Model Odds Ratio (95
Gender, female versus male 2.194
Age, yrs 0.984
Waist circumference, cm 0.951
Diabetes mellitus, absence versus presence 17.1
CHD, absence versus presence 1.751
Total cholesterol, mg/dl 1.011
Ln triglycerides, mg/dl 0.083
Non–HDL-cholesterol, mg/dl 1.010
LDL-cholesterol, mg/dl 1.011
ApoB, mg/dl 1.027
Total cholesterol 95th percentile, yes versus no 4.795
HD  coronary heart disease; Ln  natural logarithm; ROC  receiver-operator characteristic; o
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Figure 1 Percentage of Subjects With Clinical Diagnosis of FCH
Percentage of subjects with clinical diagnosis of familial combined hyperlipidemia
sent the percentage in the whole group and in several subgroups. Subgroups have
LDLR mutation in the regression analysis. apoB  apolipoprotein B; APOE()  s
hyperlipidemia; chol  cholesterol; DM()  subjects without diabetes mellitus.olic abnormalities coexisting with elevated blood cholesterol
nd triglycerides levels is highly predictive of the absence of
DLR defects in patients with combined hyperlipidemia.
POE mutations. The results of APOE genotyping are
nteresting, inasmuch as 4 of 115 patients (3.5%) with a
linical diagnosis of FCH and no LDLR mutations had
olecular defects in APOE that are characteristic of type III
yperlipidemia or dysbetalipoproteinemia, which also pre-
ents with combined hyperlipidemia overlapping that of
linical Diagnosis of FCH
tients With Clinical Diagnosis of FCH
nfidence Interval) p Value
Area Under the
Curve in ROC Analysis
–5.077) 0.067 0.593
–1.021) 0.386 0.554
–0.993) 0.023 0.630
289) 0.002 —
–5.502) 0.337 0.542
–1.018) 0.003 0.721
–1.059) 0.055 0.615
–1.017) 0.008 0.700
–1.020) 0.007 0.730
–1.041) 0.000 0.735
–21.399) 0.040 0.599
reviations as in Tables 1 and 2.
With LDLR Mutation
and with low-density lipoprotein receptor (LDLR) gene mutation. Columns repre-
defined according to the factors independently associated with the presence of
without the APOE E2/E2 genotype or other rare APOE allele associated withith C
in Pa
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LDLR Mutations in FCH November 4, 2008:1546–53CH (21). These findings indicate that APOE genotyping
s mandatory before a diagnosis of FCH is considered.
trengths and limitations. This study has the strengths of
cross-sectional design in a sizeable cohort of FCH patients
efined by strict clinical criteria and assessed for LDLR
efects with up-to-date techniques of molecular testing.
here are also limitations to our study. One limitation is
hat we did not perform family studies to examine segrega-
ion and genotype–phenotype interactions of the detected
DLR mutations. Another limitation is that the observed
requency of LDLR defects may not be extrapolated to other
CH cohorts showing less severe lipid phenotypes. The
resent series has an inherent selection bias toward more
evere lipid abnormalities and may not be representative of
CH patients within the general population because pa-
ients are referred to our lipid clinics mainly by general
ractitioners because of severe dyslipidemia or refractoriness
o hypolipidemic treatment. The frequency of LDLR mu-
ations in FCH patients with milder lipid phenotypes is
robably lower than that reported here. An alternative
xplanation for the relatively high frequency of LDLR
utations in our FCH patients could be that the genetic
efects were not pathogenic. However, this is highly im-
robable for several reasons: most of the detected LDLR
efects have been previously reported as causative mutations
n FH; some of them generate truncated proteins and/or
heir deleterious effects have been confirmed “in vitro”; the
oss of receptor function has been demonstrated in family
tudies for many of them; and none of the mutations found
ave been observed in normolipidemic populations.
onclusions
wo important conclusions can be derived from this work.
irst, pending the availability of a genetic or biochemical
arker for a reliable diagnosis of FCH, the exclusion of
DLR gene defects is highly recommended for patients
ith this clinical diagnosis who present with severe eleva-
ions of total cholesterol or apoB levels. This exclusion could
e particularly important for research purposes and to limit
he heterogeneity observed in many biochemical and genetic
tudies of FCH cohorts. Second, the diagnostic criteria for
H should not exclude patients with combined hyperlipid-
mia. In this situation, the total cholesterol or apoB level
ight be a better diagnostic tool than LDL-cholesterol, and
alues above 335 or 185 mg/dl, respectively, should raise the
uspicion of FH and prompt a search for LDLR mutations.
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APPENDIX
or a supplemental table on the description of the LDLR mutations found in
ubjects with mixed hyperlipidemia, please see the online version of this
rticle.
